Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
GrayBug logo — Saving Sight Through Transformative Science.

GrayBug

Saving Sight Through Transformative Science.

Founded 2011 United States Redwood City, United States 4 employees Series C Total: $129.24M Biotechnology, Health Care +1

General Information

Company Name GrayBug
Founded Year 2011
Location United States Redwood City, United States
Employees 4
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series C
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with GrayBug. To contact GrayBug, visit graybug.vision.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does GrayBug compare?

A PDF of GrayBug and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting GrayBug soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About GrayBug

GrayBug, founded in 2011, is a biopharmaceutical company committed to developing transformative medicines for ocular diseases. With the slogan, "Saving Sight Through Transformative Science.", they are leveraging technology licensed from the Johns Hopkins University School of Medicine.

Based in Redwood City, California and Baltimore, Maryland, GrayBug operates in the Biotechnology, Health Care, and Pharmaceutical sectors, positioning itself at the intersection of innovation and healthcare solutions.

The company secured an impressive $80.00M Series C investment on 20 August 2019, signaling strong confidence from notable investors including Hatteras Venture Partners, OrbiMed, C-Bridge Capital, and Deerfield Capital Management. This financial backing highlights the significant interest and potential perceived in GrayBug's mission and its innovative contributions to the field of eye health.

Business keywords: Biopharmaceutical, Ocular Diseases, Transformative Medicines, Johns Hopkins University Technology, Calcium Release-Activated Calcium Channels, Immune Response Modulation, Tissue Cell Protection, Inflammatory Diseases, Proprietary Technology, Therapeutic Development, Vision Health, Pharmaceutical R&D, Licensing and Partnerships, Ophthalmology

Services & Products

Slot Games
Live Casino
Sports Betting
Lottery Services
Instant Deposit and Withdrawal

Target Customers

Online Gamblers Casino Enthusiasts Sports Bettors Esports Fans Individuals seeking Lottery Games

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $80.00M 4
Hatteras Venture Partners OrbiMed C-Bridge Capital
Hatteras Venture Partners, OrbiMed +2
20 Aug 2019
Series B $44.50M 4
Hatteras Venture Partners OrbiMed
Hatteras Venture Partners, OrbiMed +2
02 May 2016
Debt Financing $750.00K -
16 Dec 2015
Series A $1.74M 2
Maryland Venture Fund Hatteras Venture Partners
Maryland Venture Fund, Hatteras Venture Partners
06 Mar 2015
Venture Round $750.00K -
07 Oct 2014
Series A $1.50M 2
Maryland Venture Fund
Maryland Venture Fund, Frank A. Bonsal
29 Oct 2013

GrayBug Alternatives & Competitors

View All Alternatives
GrayBug vs
Tollys
Tollys France

A new dimension in immuno-oncology

Series A
1 employees
Biopharma, Biotechnology
GrayBug vs
Tessa Therapeutics Ltd
Tessa Therapeutics Ltd Singapore

A clinical-stage biotech company developing autologous and allogeneic cell therapies for the treatme...

Grant
31 employees
Biotechnology, Health Care
GrayBug vs
Oxyrane
Oxyrane United Kingdom

Series D
6 employees
Biopharma, Biotechnology
View all alternatives

FAQ About GrayBug

Saving Sight Through Transformative Science.
GrayBug was founded in 2011.
GrayBug is headquartered in Redwood City, United States.
GrayBug operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Ocular Diseases, Transformative Medicines and Johns Hopkins University Technology. Its customers include Online Gamblers, Casino Enthusiasts and Sports Bettors.
GrayBug has a B2B and B2B2C business model. Its revenue comes from Product Sales and Licensing.
GrayBug has approximately 4 employees.
GrayBug has completed 6 funding rounds, raising a total of $129.24M. The latest funding stage is Series C.
GrayBug offers: Slot Games, Live Casino, Sports Betting, Lottery Services, Instant Deposit and Withdrawal.
Top alternatives and competitors to GrayBug include Tollys, Tessa Therapeutics Ltd, Oxyrane, Intract Pharma, OptiScan Biomedical Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
GrayBug and Tollys are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for GrayBug, https://bouncewatch.com/company/graybug, updated 6 August 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout